CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 93 enrolled
Drug / intervention
Colchicine Tablets +1 moredrug
Likely dose
Colchicine Tablets 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04355143
NCT04355143Phase 2Completed
CompareCT.gov

Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 (Coronavirus Disease 2019) Patients (COLHEART-19)

University of California, Los Angeles·interventional·Posted Apr 21, 2020·Updated Nov 3, 2022

In Brief

A Phase 2 clinical trial evaluating Colchicine Tablets and Current care per UCLA treating physicians for COVID-19. Completed, enrolled 93 participants across 3 sites.

Detailed Summary

Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm). Importantly, this adaptive trial design allows for patients in either study arm to receive other investigational drugs for COVID-19 as new science emerges.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 21, 2020
Enrollment StartMay 1, 2020
Primary CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.2 years ago

Interventions

Colchicine Tabletsdrug

COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.

Current care per UCLA treating physiciansother

Current care